Purpose: There is overwhelming interest to use actinium-225 ([225Ac]Ac) to develop targeted α therapies. Antibody–drug conjugates (ADC) are highly cytotoxic. Combining [225Ac]Ac with an ADC to develop an antibody–drug radioconjugate [225Ac]Ac–macropa–trastuzumab(T)–PEG6–emtansine (DM1), is expected to be more effective than its ADC (T–PEG6–DM1) against breast cancer. Experimental Design: [89Zr]Zr–p-isothiocyanatobenzyl desferrioxamine (DFO)–T–PEG6–DM1 (imaging) and [225Ac]Ac–macropa–T–PEG6–DM1 (radiotherapy) were developed. Biodistribution and safety evaluations of [225Ac]Ac–macropa–T-PEG6–DM1 were carried out in non–tumor-bearing BALB/c mice. MicroPET imaging and biodistribution were done using [89Zr]Zr-DFO–T–PEG6–DM1, and radiotherapy using [225Ac]Ac–macropa–T–PEG6–DM1 was carried out in athymic BALB/c nude mice bearing trastuzumab-resistant HCC1954 and trastuzumab-DM1 (T-DM1)/trastuzumab-resistant JIMT-1 tumor-bearing mice. Results: After 7 days of incubation at 37°C, [225Ac]Ac–macropa–T–PEG6–DM1 was stable in both human serum (89.2% ± 0.9%) and PBS (82.8% ± 0.4%). T–PEG6–DM1 (8 mg/kg) and [225Ac]Ac–macropa–T–PEG6–DM1 (3 × 18 kBq) administered separately in non–tumor-bearing mice 10 days apart were well tolerated biochemically and hematologically. Imaging and biodistribution showed high tumor uptake of [89Zr]Zr-DFO–T–PEG6–DM1 in tumor-bearing mice at 120 hours after injection: 38.1% ± 2.8% IA/g (HCC1954) and 14.6% ± 1% IA/g (JIMT-1). In HCC1954 tumor-bearing mice, all treatment groups had complete remission (8/8), indicative of the responsiveness of the xenograft to T-DM1–based treatments, whereas for JIMT-1 xenografts (having 1/8 complete remission) at 23 days after treatment, tumor volumes were 332.1 ± 77.5 vs. 244.6 ± 63 vs. 417.9 ± 62.1 vs. 102.4 ± 18.5 for the saline (negative control), T-DM1 (positive control), T–PEG6–DM1, and [225Ac]Ac–macropa–T–PEG6–DM1, respectively. Conclusions: [225Ac]Ac–macropa–T–PEG6–DM1 is more potent than ADC against trastuzumab-resistant breast cancer and necessitates clinical translation.
EGFR is expressed in approximately 80% to 85% of colorectal cancers. Although anti-EGFR antibodies benefit some patients with colorectal cancer, tumors with Kirsten rat sarcoma viral oncogene (KRAS) or B-rapidly accelerated fibrosarcoma (BRAF), a proto-oncogene serine/threonine protein kinase, mutations are resistant. In this study, we developed a theranostic approach that uses an anti-EGFR antibody–drug conjugate labeled with either [225Ac]Ac or [89Zr]Zr and evaluated the strategy against KRAS- and BRAF-mutant EGFR-positive colorectal cancer models. The antibody–drug radioconjugate [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1 showed enhanced in vitro cytotoxicity compared with the unlabeled antibody–drug conjugate nimotuzumab-PEG6-DM1. [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1 extended the survival of mice bearing all tested xenografts compared with untreated and nimotuzumab-PEG6-DM1–treated controls. For the BRAFV600E-mutant xenograft, the median survival was not reached following treatment with [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1, whereas it was 24.5 and 39 days for the saline-treated and nimotuzumab-PEG6-DM1–treated groups, respectively. Micro-PET/CT imaging using the nonoverlapping anti-EGFR radioimmunoconjugate [89Zr]Zr-DFO-matuzumab before and after treatment of orthotopic colorectal cancer xenografts showed that 1/5 mice in the treatment group had complete remission, whereas metastatic spread was prevented in the other mice (4/5). These results show that treatment with [225Ac]Ac-macropa-nimotuzumab-PEG6-DM1 is a potential therapeutic approach for KRAS- and BRAFV600E-mutant metastatic colorectal cancer. Significance: Radiolabeling with [225Ac]Ac improves the efficacy of an anti-EGFR antibody-drug conjugate in KRAS- and BRAFV600E-mutant colorectal cancer, providing hope for patients with these mutations who do not qualify for EGFR-targeted therapies.
Purpose:Mucin 16 (MUC-16)–targeted antibodies can deliver contrast agents (diagnostic) and/or cytotoxic payloads (therapy) to the tumor site. MUC-16 is overexpressed in 80% of epithelial ovarian cancer (EOC) and 65% of pancreatic ductal adenocarcinomas (PDAC). We previously developed a fully human antibody against MUC-16 (M16AB) and demonstrated the utility of [89Zr]Zr-DFO-M16AB as a PET imaging agent. In this study, we developed the [225Ac]Ac-Macropa-M16AB radioimmunoconjugate and studied its efficacy against MUC-16–positive EOC and PDAC xenografts. Experimental Design:[225Ac]Ac-Macropa-M16AB was characterized in vitro. The pharmacokinetics, biodistribution, hematologic safety, and dosimetry of [225Ac]Ac-Macropa-M16AB were studied in healthy mice. The efficacy of two doses (13 or 18.6 kBq) [225Ac]Ac-Macropa-M16AB administered 10 days apart was evaluated in the MUC-16–expressing cell line–derived xenograft (CDX) SW1990 and in mice bearing PDAC and EOC patient-derived xenografts (PDX) with varying MUC-16 expression levels. Results:In SW1990 CDX models, [225Ac]Ac-Macropa-M16AB induced complete remission (CR) in 16.7% of mice, whereas the remaining 83.3% exhibited durable tumor growth suppression for ≥50 days; however, all control animals progressed rapidly. [225Ac]Ac-Macropa-M16AB treatment resulted in 100% sustained CRs in high and medium MUC-16–expressing EOC and PDAC PDXs. In the low MUC-16–expressing EOC PDX, the treatment demonstrated tumor growth inhibition and prolonged survival. [225Ac]Ac-Macropa-M16AB (3 × 15 kBq) administered in naive mice 10 days apart was tolerated biochemically and hematologically, with only mild, dose-dependent hepatic and splenic changes observed on histopathology. Conclusions:The effectiveness of [225Ac]Ac-Macropa-M16AB, which is dependent on the expression levels of MUC-16, indicates potential benefits for patients with EOC and PDAC when translated into clinical trials.